These discoveries have transformed the outcomes of advanced lung cancer with the development of tyrosine kinase inhibitors (TKI) targeting driver mutations such as EGFR directed TKIs and immune checkpoint inhibitors (ICI) which unleash the host immune system against tumor cells (19–24). Here, EGFR is linked to neoplasm.